AMO Pharma raises $25 million in private equity financing AMO Pharma Small , a privately held biopharmaceutical company concentrating on debilitating illnesses with limited or no treatment plans, announced today that the company offers raised $25 million in private equity funding from Woodford Investment Management . This initial expenditure came from the Woodford Patient Capital Trust Click here . Financing will support Company efforts to progress two clinical-stage pipeline property targeting uncommon muscular and central anxious system disorders. The financing will also be used to increase the AMO Pharma pipeline through acquisition of extra development-stage items. Following our effective acquisition of two promising compounds, our financing with Woodford provides us with the resources we need to continue to rapidly advance our clinical development programs while also positioning us to further increase our pipeline.
These accumulations are indicative of the severity of the condition. As the disease progresses, retinal sensory cells in the central vision area are damaged, leading to lack of central vision. The cell biological mechanisms underlying protein accumulations remain unknown mainly. For the very first time ever, the present research showed that AMD can be connected with impaired lysosomal autophagy, which is an important clean-up mechanism of the fundus of the attention. This renders the cells in the fundus of the attention unable to get rid of old, deformed or elsewhere faulty proteins, which, in turn, leads to the advancement of protein reduction and accumulations of vision. The scholarly study could be regarded as a breakthrough, as the results change our understanding of the pathogenesis of AMD and also open fresh avenues for the treatment of the dry type of AMD.